Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A1 | Q14973 | 2/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.43 |
| ▸ | TOP2A | P11388 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17817305 | 1.00 | SLC10A1 (0.43) | SLC10A1PTPN1TOP2AUSP2LMNA | |
| SCHEMBL23016841 | 0.88 | PTPN1 (0.43) | SLC10A1PTPN1TOP2AUSP2LMNA | |
| SCHEMBL23016840 | 0.88 | PTPN1 (0.43) | SLC10A1PTPN1TOP2AUSP2LMNA | |
| SCHEMBL17832965 | 0.87 | SLC10A1 (0.60) | SLC10A1GPBAR1 | |
| SCHEMBL17817298 | 0.87 | SLC10A1 (0.60) | SLC10A1GPBAR1 | |
| SCHEMBL17832966 | 0.82 | PTPN1 (0.52) | SLC10A1PTPN1TOP2AUSP2LMNA | |
| SCHEMBL15074887 | 0.73 | SLC10A1 (0.75) | SLC10A1CA9CA1CA2 | |
| SCHEMBL3786701 | 0.73 | SLC10A1 (0.62) | SLC10A1GPBAR1 | |
| SCHEMBL17817302 | 0.73 | SLC10A1 (0.62) | SLC10A1GPBAR1 | |
| SCHEMBL3781420 | 0.73 | SLC10A1 (0.80) | SLC10A1PTPN1TOP2AUSP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | ALTIUM GROWTH FUND, LP | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | RXRA, RXRG, CX3CR1 | SLC10A1 1776/4885PTPN1 1769/4885TOP2A 2120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.